The lower concentrations of KOR and MOR agonists in cholestatic patients may result from increased hepatic metabolism or increased renal clearance, which warrants further investigations in animal models of intrahepatic cholestasis. The gene discussed is OPRK1; the disease is intrahepatic cholestasis.